Laurion Capital Management’s AbbVie ABBV Stock Holding History

Laurion Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,055,000	Closed	-$244M	–	307
2025 Q3	$244M	Buy	+1,055,000	New	+$215M	4.2%	3
2024 Q3	–	Sell	-80,000	Closed	-$13.7M	–	281
2024 Q2	$13.7M	Buy	+80,000	New	+$13.3M	0.16%	94
2023 Q2	–	Sell	-150,000	Closed	-$23.9M	–	586
2023 Q1	$23.9M	Sell	150,000 -850,000	-85%	-$130M	0.16%	125
2022 Q4	$162M	Buy	+1,000,000	New	+$153M	0.76%	42
2022 Q2	–	Sell	-20,200	Closed	-$3.27M	–	458
2022 Q1	$3.27M	Sell	20,200 -62,400	-76%	-$9.06M	0.04%	178
2021 Q4	$11.2M	Sell	82,600 -213,300	-72%	-$25.2M	0.11%	119
2021 Q3	$31.9M	Buy	+295,900	New	+$33.8M	0.13%	154
2020 Q2	–	Sell	-126,700	Closed	-$9.65M	–	876
2020 Q1	$9.65M	Sell	126,700 -237,000	-65%	-$20.2M	0.11%	179
2019 Q4	$32.2M	Sell	363,700 -382,200	-51%	-$31.7M	0.25%	93
2019 Q3	$56.5M	Buy	745,900 +369,200	+98%	+$25.3M	0.42%	54
2019 Q2	$27.4M	Buy	376,700 +358,700	+1,993%	+$28.2M	0.27%	89
2019 Q1	$1.45M	Sell	18,000 -73,800	-80%	-$6.04M	0.02%	451
2018 Q4	$8.46M	Sell	91,800 -474,000	-84%	-$41.7M	0.15%	176
2018 Q3	$53.5M	Buy	565,800 +58,200	+11%	+$5.52M	0.52%	20
2018 Q2	$47M	Buy	507,600 +30,500	+6%	+$2.98M	0.38%	58
2018 Q1	$45.2M	Sell	477,100 -65,000	-12%	-$7.14M	0.36%	63
2017 Q4	$52.4M	Buy	542,100 +222,100	+69%	+$20.9M	0.27%	79
2017 Q3	$28.4M	Sell	320,000 -58,800	-16%	-$4.48M	0.13%	140
2017 Q2	$27.5M	Buy	378,800 +104,200	+38%	+$7.01M	0.15%	133
2017 Q1	$17.9M	Buy	274,600 +154,500	+129%	+$9.71M	0.13%	189
2016 Q4	$7.52M	Buy	+120,100	New	+$7.33M	0.07%	274

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Laurion Capital Management's ABBV Position: Q2 2026 in Review

Laurion Capital Management increased its AbbVie (ABBV) stake by 402% in Q2 2026, buying an estimated $7.27M and bringing the position to 42,168 shares worth $10.6M. The position accounts for 0.27% of the portfolio, ranked #85.

Laurion Capital Management first reported a position in ABBV in Q2 2015 and has held it in 22 quarters since. The position peaked at $49.5M in Q2 2016. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Laurion Capital Management held 42,168 shares of AbbVie worth $10.6M as of Q2 2026.
Laurion Capital Management bought 33,773 AbbVie shares in Q2 2026, an estimated $7.27M.
AbbVie made up 0.27% of Laurion Capital Management's portfolio in Q2 2026, its #85 holding.
Laurion Capital Management first reported a position in AbbVie in Q2 2015 and has held it in 22 quarters since.
Laurion Capital Management's AbbVie position peaked at $49.5M in Q2 2016.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.